You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 20, 2023

Thailand Prepares to Renew Drug Marketing Authorizations as First Expiration Nears

Thailand is preparing to open its first renewal period for drug marketing authorizations (MAs) since the passage of the Drug Act (No. 6) B.E. 2562 (2019).

Before 2019, MAs for pharmaceuticals and vaccines in Thailand had lifelong validity. The 2019 Drug Act stipulated that all new MAs would be valid for seven years and could be renewed.

The 2019 law also set out expiration dates for existing pharmaceutical products registered and approved prior to the implementation of the law (i.e., before October 13, 2019):

  • Drug MAs issued before January 1, 1997, expire on October 13, 2024.
  • Drug MAs approved between January 1, 1997, and December 31, 2007, expire on October 13, 2026.
  • Drug MAs approved between January 1, 2008, and October 13, 2019, expire on October 13, 2028.

Based on these dates, the first renewal period for drug MAs will commence in the fourth quarter of 2023. To facilitate the renewal process, the Thai Food and Drug Administration (FDA) has publicized draft regulations and notifications on the required application form and documents, the rules and conditions, and the process for renewing an MA.

In May 2023, the Thai FDA issued Ministerial Regulation Re: Renewal of Drug MA Licenses B.E. 2566 (2023) to prescribe the essential requirements for filing a renewal application:

  • To renew a drug MA, holders must submit their renewal application to the Thai FDA within the one-year period before the MA’s expiration date.
  • Renewal applications can only be submitted online via the Thai FDA’s electronic system.
  • The Thai FDA will grant approval for an MA renewal if the following conditions are satisfied:
    • The documents in relation to efficacy and safety are up-to-date, accurate, and in accordance with academic principles.
    • The specification and analytical method comply with the official pharmacopeias as prescribed in the Drug Act, as amended. For noncompendial specifications or methods, justification or evidence that substantiates the quality, safety, and efficacy of the drug product must also be provided.

The ministerial regulation also provided examples of required information and documents:

  • Evidence of the quality, efficacy, and safety of the drug products.
  • Label and package insert.
  • Documents demonstrating the patent number or petty patent number as announced in Thailand.
  • GMP (Good Manufacturing Practice) clearance letter (for imported drug products).

It is expected that the official document checklist and other requirements will be published in the fourth quarter of 2023. MA holders should recheck the renewal period for their pharmaceutical products and start preparing the most up-to-date version of the drug registration dossier.

Those who obtained conditional approval for COVID-19 drugs and wish to continue their related business operations must apply for a new conditional approval under Thailand’s new rules for conditional approval before the expiration of their current MA.

For more details on drug MA renewal, please contact Kittiya Nopparatrungroj at [email protected] or +66 2056 5750.

RELATED INSIGHTS​ 

September 19, 2019
The August 2019 edition of Global Regulatory Press’ Journal of Medical Device Regulation  features a Vietnam overview authored by two of Tilleke & Gibbins’ regulatory affair specialists in the jurisdiction—Hien Thi Thu Vu, head of the regulatory affairs team in Vietnam, and Mai Thi Le, regulatory affairs consultant in Vietnam.
September 19, 2019
Dr. Atthachai Homhuan, manager of regulatory affairs at Tilleke & Gibbins, recently contributed the Thailand overview for the May 2019 edition of Global Regulatory Press’ Journal of Medical Device Regulation —an industry-specific journal that provides an insider’s perspective into the regulatory world surrounding medical devices in jurisdictions around the world.In the Thailand overview, Dr. Atthachai covers the following topics:
September 5, 2019
On Friday August 30, 2019, a Notification of the Thai Ministry of Public Health (“MOPH Notification”) was published in the Government Gazette. The MOPH Notification went into effect on August 31, 2019, one day after its publication.This MOPH Notification outlines another Thai Government initiative in connection with the free cannabis policy, this time carving out further aspects of marijuana and hemp use from the stringent regulations under the Narcotics Act.
September 4, 2019
The 2019 edition of Thomson Reuters’ Practical Law Life Sciences Global Guide  has been released, with its Pharmaceutical Intellectual Property and Competition Law in Cambodia chapter written by practitioners from Tilleke & Gibbins’ Phnom Penh office.The guide is a Q&A-style overview of the regulatory frameworks for the life sciences industries across jurisdictions worldwide. This chapter on pharmaceutical IP and competition law in Cambodia addresses the following issues in the country’s legal landscape for life sciences: